Editorial: weighing the global risk of cancer with thiopurines in inflammatory bowel disease—Authors' reply

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|47|5|690-691

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.47, Iss.5, 2018-03, pp. : 690-691

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Editorial: weighing the global risk of cancer with thiopurines in inflammatory bowel disease

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 5, 2018-03 ,pp. : 689-690

John Wiley & Sons Inc

Access to resources Recommend Favorite

Systematic review with meta‐analysis: thiopurines decrease the risk of colorectal neoplasia in patients with inflammatory bowel disease

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 3, 2018-02 ,pp. : 318-331

John Wiley & Sons Inc

Access to resources Recommend Favorite

Use of Azathioprine and the Risk of Cancer in Inflammatory Bowel Disease

By Pasternak Björn   Svanström Henrik   Schmiegelow Kjeld   Jess Tine   Hviid Anders  

American Journal of Epidemiology, Vol. 177, Iss. 11, 2013-06 ,pp. : 1296-1305

Oxford University Press

Access to resources Recommend Favorite

Letter: low muscle mass and disordered eating as causes of osteopenia in inflammatory bowel disease – authors' reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 12, 2015-06 ,pp. : 1304-1305

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: the safety of herpes zoster vaccination for patients with inflammatory bowel disease being treated with anti‐TNF medications—authors’ reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 3, 2018-02 ,pp. : 448-448

John Wiley & Sons Inc

Access to resources Recommend Favorite